Overview
This series explains what the evidence shows after GLP-1 receptor agonists stop: weight commonly returns, often faster early and slower later, while some net loss and cardiometabolic benefit may remain. It connects the STEP 1 semaglutide extension with a 48-study review and a six-trial model, keeping regain percentages tied to their denominator and time window. The evidence supports a common population pattern, not a personal timetable; the projected long-term plateau, mechanisms, body composition, and best maintenance approach remain uncertain.
Learning outcomes
- Substantial weight regain is common after GLP-1 treatment stops, with faster early change and slower later change.
- A regain percentage describes the share of treatment loss that returned, not automatic return to starting weight.
- In selected STEP 1 completers, one year off semaglutide and support left a 5.6% mean net loss after 11.6 percentage points returned.
- The long-term plateau, mechanisms, body composition, and best maintenance pathway remain uncertain.
Keywords
Preview every chapter · Unlock full text, audio, and video from chapter 4
PlansFAQ
What happens after GLP-1 treatment stops?
Substantial weight regain is common, often faster early and slower later, while some net loss and cardiometabolic benefit may remain.
How much weight returns after stopping GLP-1 treatment?
The six-trial model estimated about 60% of treatment loss regained by 52 weeks and projected 75.3%, but the latter is extrapolated, not a lifetime measurement.
Does weight regain mean GLP-1 treatment failed?
No. Treatment can produce a real loss while much of it reverses after support is withdrawn; residual benefit may remain.
Why does weight return after GLP-1 treatment stops?
Weight can return when drug support is removed while compensatory physiology, appetite, behavior, environment, and support interact; their exact contributions remain uncertain.